October 1, 2024

Supplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Supplementary Figure S4 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.

Me gusta

Guardar

Cite This Study

Sudhakar et al. (Tue,) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efeef2 https://doi.org/https://doi.org/10.1158/1535-7163.27142590

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024
2Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024
3Supplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024
4Supplementary Figure S3 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024
5Supplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024

Me gusta

Guardar